ONCOTELIC PUBLISHED ITS FOURTH PUBLICATION ON TGFB2 THERAPEUTICS
28. Oktober 2024 08:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today its fourth publication of its TGFB2 series. Clinical data demonstrated that...
Processa Pharmaceuticals Names Dr. Steven Cha Senior Vice President of Clinical Research
30. April 2024 08:00 ET
|
Processa Pharmaceuticals, Inc.
Brings extensive experience in all phases of oncology drug development HANOVER, Md., April 30, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (Processa or the Company), a...
Linkage of Cancer and Lupus in Gliomas Patients
25. März 2024 08:10 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) announced today the peer reviewed publication of Transforming Growth Factor Beta 2 (TGFB2) mRNA...
Invitation to Participate in STOP-PC Clinical Trial
04. März 2024 08:17 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) invites participation in our STOP-PC clinical trial which is now open for recruitment. Additional...
Oncology Drug Discovery & Development Market Expected to Grow at a CAGR of 18.2% from 2023 to 2031 | Reveals InsightAce Study
22. November 2023 04:20 ET
|
InsightAce Analytic Pvt. LTd.
Jersey City, NJ, Nov. 22, 2023 (GLOBE NEWSWIRE) -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Oncology Drug Discovery & Development Market-...
Global Oncology Drug Discovery & Development Market Analysis
25. Oktober 2023 07:00 ET
|
Global Market Estimates
Brooklyn, New York, Oct. 25, 2023 (GLOBE NEWSWIRE) -- According to a new market research report published by Global Market Estimates, the global oncology drug discovery & development market is...
Sapu BioScience and Cromos Pharma initiating P201 – A Registrational trial for OT-101 in Pancreatic Cancer
23. August 2023 07:10 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC) ("Oncotelic", the "Company" or "We" or “Our”), announced today its joint venture partner, GMP...
High Intra-Tumor TGF-β2 Predicts Poor Survival in Pediatric Cancer of the Brainstem
13. März 2023 08:00 ET
|
Oncotelic Therapeutics, Inc.
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc (OTCQB:OTLC)...
ONCOTELIC REPORTS Q2 2022 COMPARED TO Q2 2021 FINANCIAL RESULTS
22. August 2022 09:00 ET
|
Oncotelic Therapeutics, Inc.
Net profit of approximately $17.0 million, upon recording fair value of investment in JV of approximately $22.6 millionReduction in expenses in Q2 2022 versus Q2 2021 by over $3.5M, AGOURA HILLS,...
Oncotelic Appoints Seymour Fein M.D. as Chief Regulatory Officer
04. Mai 2022 07:00 ET
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), today announced the appointment of Dr. Seymour Fein as its Chief...